PURPOSE: Patients with brainstem metastases have limited treatment options. In this study, we reviewed outcomes after stereotactic radiosurgery (SRS) in the management of patients with brainstem metastases. METHODS AND MATERIALS: Records were reviewed of 22 consecutive patients presenting with brainstem metastases who underwent SRS. The most frequent primary malignancy was the lung (n = 11), followed by breast (n = 3) and kidney (n = 2). Three patients (14%) also underwent whole-brain radiation therapy (WBRT). The median tumor volume was 0.9 mL (range, 0.1-3.3 mL); the median tumor margin dose was 16 Gy (range, 14-23 Gy). RESULTS: Median survival time after SRS was 8.5 months. Although local tumor control was achieved in all patients with imaging follow-up (n = 19), 5 patients died from development and progression of new brain metastases. Two patients (9%) had symptom improvement after SRS, whereas 1 patient (5%) developed a new hemiparesis after SRS. CONCLUSIONS: Radiosurgery is safe and provides a high local tumor control rate for patients with small brainstem metastases. Patients with limited systemic disease and good performance status should be strongly considered for SRS.
PURPOSE:Patients with brainstem metastases have limited treatment options. In this study, we reviewed outcomes after stereotactic radiosurgery (SRS) in the management of patients with brainstem metastases. METHODS AND MATERIALS: Records were reviewed of 22 consecutive patients presenting with brainstem metastases who underwent SRS. The most frequent primary malignancy was the lung (n = 11), followed by breast (n = 3) and kidney (n = 2). Three patients (14%) also underwent whole-brain radiation therapy (WBRT). The median tumor volume was 0.9 mL (range, 0.1-3.3 mL); the median tumor margin dose was 16 Gy (range, 14-23 Gy). RESULTS: Median survival time after SRS was 8.5 months. Although local tumor control was achieved in all patients with imaging follow-up (n = 19), 5 patients died from development and progression of new brain metastases. Two patients (9%) had symptom improvement after SRS, whereas 1 patient (5%) developed a new hemiparesis after SRS. CONCLUSIONS: Radiosurgery is safe and provides a high local tumor control rate for patients with small brainstem metastases. Patients with limited systemic disease and good performance status should be strongly considered for SRS.
Authors: Khinh Ranh Voong; Benjamin Farnia; Qianghu Wang; Dershan Luo; Mary F McAleer; Ganesh Rao; Nandita Guha-Thakurta; Anna Likhacheva; Amol J Ghia; Paul D Brown; Jing Li Journal: Neurooncol Pract Date: 2015-03-03
Authors: Jeremy M Kilburn; Thomas L Ellis; James F Lovato; James J Urbanic; J Daniel Bourland; J Daniel Bourland; Michael T Munley; Allan F Deguzman; Kevin P McMullen; Edward G Shaw; Stephen B Tatter; Michael D Chan Journal: J Neurooncol Date: 2014-02-07 Impact factor: 4.130
Authors: Paul J Kelly; Yijie Brittany Lin; Alvin Y C Yu; Alexander E Ropper; Paul L Nguyen; Karen J Marcus; Fred L Hacker; Stephanie E Weiss Journal: J Neurooncol Date: 2011-01-07 Impact factor: 4.130
Authors: José M Samblás; Kita Sallabanda; José C Bustos; José A Gutiérrez-Díaz; Carmen Peraza; César Beltrán; Pilar María Samper Journal: Clin Transl Oncol Date: 2009-10 Impact factor: 3.405
Authors: Andrew F Lamm; Ameer L Elaimy; Alexander R Mackay; Robert K Fairbanks; John J Demakas; Barton S Cooke; Christopher M Lee; Blake S Taylor; Wayne T Lamoreaux Journal: Case Rep Oncol Med Date: 2012-09-29
Authors: Jonathan E Leeman; David A Clump; Rodney E Wegner; Dwight E Heron; Steven A Burton; Arlan H Mintz Journal: Radiat Oncol Date: 2012-07-11 Impact factor: 3.481
Authors: Andrew F Lamm; Ameer L Elaimy; Wayne T Lamoreaux; Alexander R Mackay; Robert K Fairbanks; John J Demakas; Barton S Cooke; Christopher M Lee Journal: ISRN Surg Date: 2013-04-11